AEON Biopharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AEON Biopharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.22M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $42.01M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($323.95M) | Mar 24, 2025 |
| FY2023 | Sep 30, 2023 | ($297.71M) | May 14, 2024 |
| FY2024 | Jul 21, 2023 | ($60.68M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($52.56M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $8.20M | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | ($3.6K) | Mar 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.80M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $72.99M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($318.44M) | Mar 24, 2025 |
| FY2023 | Sep 30, 2023 | ($283.71M) | May 14, 2024 |
| FY2024 | Jul 21, 2023 | ($29.64M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($48.43M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($1.94M) | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | ($3.6K) | Mar 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.09M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $14.18M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $13.24M | Mar 24, 2025 |
| FY2024 | Jul 21, 2023 | $19.80M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $34.75M | Mar 29, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.21M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $13.64M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $9.95M | Mar 24, 2025 |
| FY2024 | Jul 21, 2023 | $9.84M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $13.68M | May 14, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.31M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($20.29M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($26.08M) | Mar 24, 2025 |
| FY2024 | Jul 21, 2023 | ($21.75M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($35.58M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($1.49M) | Apr 10, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.0K | Mar 30, 2026 |
| FY2023 | Dec 31, 2022 | $306.0K | May 14, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.56M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.14M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $6.85M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $10.78M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $276.95M | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | $81.0K | Mar 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.59M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $31.71M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $159.89M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $143.24M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $17.88M | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | $59.6K | Mar 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($153.04M) | May 14, 2024 |
| FY2023 | Dec 31, 2022 | ($287.50M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($16.93M) | Apr 10, 2023 |
| FY2022 | Dec 31, 2020 | $21.4K | Apr 10, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($470.82M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($431.60M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($473.60M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($474.84M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($16.96M) | Apr 10, 2023 |
| FY2021 | Dec 31, 2020 | ($3.6K) | Mar 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.01M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $13.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $5.16M | Mar 24, 2025 |
| FY2024 | Jul 21, 2023 | $31.20M | Mar 24, 2025 |
| FY2023 | Jan 6, 2023 | $31.20M | May 14, 2024 |
| FY2023 | Dec 31, 2022 | $9.75M | May 14, 2024 |
| FY2021 | Dec 31, 2021 | $497.4K | Mar 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 77 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (627) | Mar 24, 2025 |
| FY2023 | Sep 30, 2023 | (8) | May 14, 2024 |
| FY2024 | Jul 21, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 14, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 72 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (627) | Mar 24, 2025 |
| FY2023 | Sep 30, 2023 | (8) | May 14, 2024 |
| FY2024 | Jul 21, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 14, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12.11M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 555,511 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 516,404 | Mar 24, 2025 |
| FY2024 | Dec 31, 2022 | 138.83M | Mar 24, 2025 |